← Back to Search

N Acetylcysteine for Cognitive Impairment

Phase 2
Waitlist Available
Led By Krista L Lanctôt, PhD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

This trial tests if taking an NAC supplement can help improve brain function in patients with mild cognitive issues who are also in a heart rehab program. NAC works by protecting brain cells from damage. N-acetylcysteine (NAC) has been studied for its potential benefits in various conditions, including brain injury, cognitive impairment, and oxidative stress.

Eligible Conditions
  • Vascular dementia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in executive function
Secondary study objectives
Change in memory
Change in processing speed

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: N-acetylcysteineActive Control1 Intervention
Participants randomized into the N-acetylcysteine arm will be receiving N-acetylcysteine for 24 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Participants randomized into the placebo arm will be receiving placebo for 24 weeks.

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
680 Previous Clinical Trials
1,565,806 Total Patients Enrolled
Krista L Lanctôt, PhDPrincipal InvestigatorSunnybrook Research Institute
2 Previous Clinical Trials
25,015 Total Patients Enrolled

Media Library

Placebo oral capsule Clinical Trial Eligibility Overview. Trial Name: NCT03306979 — Phase 2
Vascular dementia Research Study Groups: N-acetylcysteine, Placebo
Vascular dementia Clinical Trial 2023: Placebo oral capsule Highlights & Side Effects. Trial Name: NCT03306979 — Phase 2
Placebo oral capsule 2023 Treatment Timeline for Medical Study. Trial Name: NCT03306979 — Phase 2
~8 spots leftby Dec 2025